Trial Profile

A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination With Pembrolizumab in Selected Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; XmAb 808 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer; Urogenital cancer
Focus Adverse reactions; First in man
Sponsors Xencor

28 Mar 2025 Planned End Date changed from 1 Dec 2027 to 1 Jun 2025.
28 Mar 2025 Planned primary completion date changed from 1 Dec 2027 to 1 Jun 2025.
28 Mar 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com